SCHEDULE: Wellington Management Boosts Qiagen Stake to 10.7%

Wellington Management Group LLP and its affiliates reported a 10.7% beneficial ownership stake in Qiagen N.V. common stock as of September 30, 2025.

Summary

• Wellington Management Group LLP, along with its affiliated entities Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, collectively reported beneficial ownership of 23,330,248 shares of Qiagen N.V. common stock.
• This aggregate ownership represents 10.7% of Qiagen N.V.'s common stock.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to previously reported beneficial ownership.
• The 'Date of Event Which Requires Filing of this Statement' is listed as September 30, 2025.
• The reporting entities hold shared voting power over 19,132,735 shares and shared dispositive power over 23,330,248 shares.
• Wellington Management Company LLP, specifically, reported shared voting power over 14,285,040 shares and shared dispositive power over 15,047,474 shares, representing 6.9% of the class under its direct reporting.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain qualitative statements or performance metrics that would indicate a positive or negative sentiment.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional investor's continued or increased stake in Qiagen N.V., a company operating in the life sciences and diagnostics industry. Such disclosures are common for large asset managers and can signal their long-term conviction in a company's prospects within its sector.

Stakeholder Impact

• Shareholders may view the significant stake held by Wellington Management as a vote of confidence, potentially influencing market perception and trading activity.
• Increased institutional ownership can lead to greater scrutiny of corporate governance and strategic decisions.

Key Dates

Keywords

Qiagen N.V., Wellington Management, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake